Mylan (NASDAQ:MYL) announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.79 by $0.03, MarketWatch Earnings reports. The firm had revenue of $2.50 billion for the quarter, compared to analyst estimates of $2.70 billion. Mylan had a return on equity of 18.96% and a net margin of 2.14%. Mylan’s quarterly revenue was down 7.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.96 earnings per share. Mylan updated its FY19 guidance to $3.80-4.80 EPS.
Shares of NASDAQ MYL opened at $17.21 on Friday. The company has a market capitalization of $9.23 billion, a P/E ratio of 3.76, a P/E/G ratio of 0.93 and a beta of 1.44. Mylan has a 12-month low of $17.13 and a 12-month high of $42.50. The company has a debt-to-equity ratio of 1.20, a quick ratio of 0.85 and a current ratio of 1.51.
In related news, insider Paul Campbell sold 11,533 shares of the firm’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $27.50, for a total value of $317,157.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.81% of the company’s stock.
A number of analysts have commented on the company. UBS Group decreased their target price on Mylan to $23.00 and set a “neutral” rating on the stock in a research report on Tuesday. BidaskClub downgraded Mylan from a “hold” rating to a “sell” rating in a research report on Monday, May 20th. Mizuho restated a “hold” rating on shares of Mylan in a research report on Tuesday, May 14th. Morgan Stanley set a $32.00 price objective on Mylan and gave the company a “buy” rating in a research report on Wednesday, May 8th. Finally, Raymond James set a $31.00 price objective on Mylan and gave the company a “buy” rating in a research report on Wednesday, May 8th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fourteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $36.95.
WARNING: This piece was first published by Rockland Register and is owned by of Rockland Register. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://rocklandregister.com/2019/05/31/mylan-myl-posts-earnings-results-beats-expectations-by-0-03-eps.html.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Further Reading: What is the market perform rating?
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.